Article

Hodgkin's Lymphoma Treatment Can Lead to Secondary Disease

Nearly 1 in 4 patients treated in childhood for Hodgkin's lymphoma developed a second type of cancer within 30 years.

Nearly 1 in 4 patients treated in childhood for Hodgkin's lymphoma developed a second type of cancer within 30 years.

While effective treatments for Hodgkin’s lymphoma have led to more people surviving the disease, these treatments can cause secondary disease for patients later in life.

A study published in a recent issue of the German journal Deutsches Ärzteblatt International noted that approximately 150 children and adolescents are diagnosed annually in Germany with Hodgkin’s lymphoma, while 9 out of every 10 patients survive. A common treatment for Hodgkin's lymphoma is both chemotherapy and radiotherapy, however, survivors of the disease may develop late sequelae depending on the type of treatment they receive.

The study evaluated which treatments are more likely to be proceeded by the development of secondary malignant neoplasia. The researchers then quantified the risk of secondary disease as a function of the treatment.

The development of secondary disease was found to be dependent on which combination of agents were used and the intensity of treatment. The study noted that some patients treated later with radiotherapy go on to develop malignant neoplasms due to the treatment, for example.

The study found that 1 in every 4 to 5 patients who were treated for the disease in childhood or adolescence developed a second type of cancer within 30 years of treatment.

The researchers concluded the findings indicate patients should be notified about the potential for late sequelae from treatment, and as a result should receive regular follow-up. It was also noted that radiotherapy in young patients should be given at lesser doses or avoided entirely.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards